首頁 > 市場調查報告書 > 製藥

骨疾病

骨關節炎藥物市場規模、佔有率和成長分析（按藥物類型、解剖部位、給藥途徑、銷售管道、最終用途和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897199

骨關節炎藥物市場規模、佔有率和成長分析（按藥物類型、解剖部位、給藥途徑、銷售管道、最終用途和地區分類）－2026-2033年產業預測

Osteoarthritis Therapeutics Market Size, Share, and Growth Analysis, By Drug Type, By Anatomy, By Route of Administration, By Sales Channel, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 166 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，骨關節炎治療市場規模將達到 101.6 億美元，到 2025 年將達到 108.6 億美元，到 2033 年將達到 185.1 億美元，預測期（2026-2033 年）的複合年成長率為 6.9%。

骨關節炎治療市場正經歷顯著成長，這主要受該疾病盛行率不斷上升的推動，尤其是在老年人中。美國有相當一部分人口患有骨關節炎，凸顯了有效治療方法的迫切性。疾病認知的進步和創新治療方法的發展進一步推動了這項需求。女性罹病風險較高，這主要是由於肌肉骨骼異常、荷爾蒙變化以及肥胖症盛行率較高等因素造成的，而肥胖症會增加骨關節炎的發生率。骨關節炎的複雜性，例如其增厚且無血管的組織，給治療帶來了挑戰。然而，關節內給藥系統的進步以及對緩解疾病藥物的關注，有望改善治療效果，並推動該領域持續的研究和開發。

骨關節炎藥物市場促進因素

骨關節炎治療市場預計將迎來顯著成長，主要促進因素是老齡化社會（尤其是北美和歐洲等已開發地區）中退化性關節退化性疾病的日益增多。隨著老齡化成長，罹患骨關節炎的風險也隨之增加，因此對有效治療方法的需求也日益成長。這一人口趨勢推動了治療方案的需求和創新，醫療保健機構和製藥公司正努力應對與這種慢性疾病管理相關的挑戰。因此，市場預計將會擴張，這反映出老年骨關節炎患者對先進治療方法的迫切需求。

限制骨關節炎藥物市場的因素

傳統骨關節炎治療方法（例如非類固醇消炎劑(NSAIDs) 和皮質類固醇）的潛在副作用是阻礙因素市場發展的重要因素。長期使用這些藥物可能導致嚴重的併發症，例如胃腸道疾病和心血管問題。因此，這些治療方法的副作用阻礙了患者的接受度，並促使人們尋求更安全的替代療法。患者偏好的這些轉變最終阻礙了傳統骨關節炎治療方法的廣泛應用，並凸顯了開發更安全、更有效的治療方案來應對這種常見疾病的必要性。

骨關節炎治療市場趨勢

在骨關節炎藥物市場，微創治療方法（例如黏彈性置換療法和生物製藥注射）的普及是一個顯著的趨勢。與傳統手術相比，這些治療方法能夠有效緩解疼痛、改善關節功能並縮短恢復時間。隨著患者和醫療服務提供者日益認知到這些療法的優勢（例如，改善治療效果和減少恢復時間），微創療法正逐漸受到重視。這種日益成長的偏好標誌著治療模式的轉變，推動了微創解決方案的創新和投資，最終將重塑骨關節炎的管理和治療方法格局。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Pfizer Inc.（USA）
Novartis AG（Switzerland）
Sanofi SA（France）
Johnson & Johnson（USA）
Eli Lilly and Company（USA）
Merck & Co., Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
AbbVie Inc.（USA）
Amgen Inc.（USA）
Regeneron Pharmaceuticals, Inc.（USA）
Flexion Therapeutics, Inc.（USA）
Seikagaku Corporation（Japan）
TissueGene, Inc.（South Korea）
Anika Therapeutics, Inc.（USA）
Ampio Pharmaceuticals, Inc.（USA）
BioDelivery Sciences International, Inc.（USA）
Bone Therapeutics SA（Belgium）
Kolon TissueGene, Inc.（South Korea）
Centrexion Therapeutics Corporation（USA）
Kiniksa Pharmaceuticals, Ltd.（Bermuda）

結論與建議

簡介目錄

Product Code: SQMIG30K2057

Osteoarthritis Therapeutics Market size was valued at USD 10.16 Billion in 2024 and is poised to grow from USD 10.86 Billion in 2025 to USD 18.51 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The osteoarthritis therapeutics market is experiencing significant growth driven by the rising prevalence of the condition, particularly among the aging population. A substantial portion of the American population suffers from osteoarthritis, underscoring the urgent need for effective treatment options. This demand is further amplified by advancements in disease understanding and the development of innovative therapies. Women are at heightened risk due to factors such as musculoskeletal abnormalities and hormonal changes, as well as a higher prevalence of obesity, which compounds the incidence of osteoarthritis. The complex nature of osteoarthritis, characterized by thick and avascular tissue, presents management challenges; however, advancements in intra-articular drug delivery systems and a focus on disease-modifying medications hold promise for enhancing treatment efficacy and fostering ongoing research and development in the field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Therapeutics Market Segments Analysis

Global Osteoarthritis Therapeutics Market is segmented by Drug Type, Anatomy, Route of Administration, Sales Channel, End Use and region. Based on Drug Type, the market is segmented into Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids and Others. Based on Anatomy, the market is segmented into Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis and Others. Based on Route of Administration, the market is segmented into Parenteral Route, Topical Route and Oral Route. Based on Sales Channel, the market is segmented into Prescription Drugs and Over-the-Counter Drugs. Based on End Use, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Therapeutics Market

The osteoarthritis therapeutics market is poised for significant growth, primarily fueled by the increasing prevalence of joint degenerative diseases among the aging population, particularly in developed regions like North America and Europe. As individuals age, the likelihood of experiencing osteoarthritis rises, creating a heightened need for effective treatment options. This demographic trend is driving both demand and innovation in therapeutic solutions, as healthcare providers and pharmaceutical companies seek to address the challenges associated with managing this chronic condition. Consequently, the market is expected to expand, reflecting the urgent need for advanced therapeutics tailored to older adults suffering from osteoarthritis.

Restraints in the Osteoarthritis Therapeutics Market

The potential side effects linked to traditional osteoarthritis treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, pose a significant limitation in the market. Long-term usage of these medications can result in serious complications, such as gastrointestinal disorders and cardiovascular problems. Consequently, the adverse effects associated with these therapies deter patients from utilizing them, prompting a search for safer alternatives. This shift in patient preference ultimately hampers the widespread adoption of conventional osteoarthritis treatments, highlighting the need for safer and more effective options in managing this prevalent condition.

Market Trends of the Osteoarthritis Therapeutics Market

The osteoarthritis therapeutics market is witnessing a significant trend towards the adoption of minimally invasive treatments, such as viscosupplementation and biologic injections. These therapies offer effective pain relief and enhance joint functionality, all while requiring less recovery time compared to traditional surgical interventions. As both patients and healthcare providers increasingly recognize the benefits of these options-namely improved outcomes and reduced downtime-minimally invasive alternatives are gaining traction. This growing preference marks a shift in treatment paradigms, encouraging innovation and investment in less invasive solutions, ultimately reshaping the landscape of osteoarthritis management and treatment approaches.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Osteoarthritis Therapeutics Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Viscosupplementation Agents
Nonsteroidal Anti-inflammatory Drugs
- Naproxen
- Aspirin
- Diclofenac
- Ibuprofen
- Celecoxib
- Meloxicam
- Piroxicam
- Ketoprofen
- Other NSAIDs
Analgesics
- Duloxetine
- Acetaminophen
Corticosteroids
Others

Global Osteoarthritis Therapeutics Market Size by Anatomy & CAGR (2026-2033)

Market Overview
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Others

Global Osteoarthritis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Parenteral Route
- Hyaluronic Acid Injections
- Corticosteroid Injections
- Platelet-rich Plasma (PRP) Injections
- Placental Tissue Matrix (PTM) Injections
- Acetylsalicylic Acid (ASA) Injections
- Others
Topical Route
Oral Route

Global Osteoarthritis Therapeutics Market Size by Sales Channel & CAGR (2026-2033)

Market Overview
Prescription Drugs
Over-the-Counter Drugs

Global Osteoarthritis Therapeutics Market Size by End Use & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Others

Global Osteoarthritis Therapeutics Market Size & CAGR (2026-2033)

North America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- US
- Canada
Europe (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flexion Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seikagaku Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TissueGene, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Anika Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ampio Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioDelivery Sciences International, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bone Therapeutics SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kolon TissueGene, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Centrexion Therapeutics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kiniksa Pharmaceuticals, Ltd. (Bermuda)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments